For research use only. Not for therapeutic Use.
Protionamide (or prothionamide) is a drug used in the treatment of tuberculosis; has also been tested for use in the treatment of leprosy.
Target: Anti tuberculosis
Although ETH and PTH are both potent drugs against M. tuberculosis (MIC = ～0.5 μg/ml) (24), they do not affect E. coli growth, even at very high concentrations (100 μg/ml), which is primarily caused by the absence of an EthA homologue in E. coli [1]. Clinical improvement was noted in 74% of the patients treated with ethionamide and in 83% of those treated with prothionamide. Therapy was well tolerated and drug-related hepatotoxicity did not require discontinuation of therapy. The 500-mg dose of both ethionamide and prothionamide resulted in loss in Mycobacterium leprae viability more rapidly than did the 250-mg dose, and prothionamide at both dose levels was superior to the equivalent dose of ethionamide [2].
| Catalog Number | I046393 |
| CAS Number | 14222-60-7 |
| Synonyms | 2-propylpyridine-4-carbothioamide |
| Molecular Formula | C9H12N2S |
| Purity | ≥95% |
| InChI | InChI=1S/C9H12N2S/c1-2-3-8-6-7(9(10)12)4-5-11-8/h4-6H,2-3H2,1H3,(H2,10,12) |
| InChIKey | VRDIULHPQTYCLN-UHFFFAOYSA-N |
| SMILES | CCCC1=NC=CC(=C1)C(=S)N |
| Reference | [1]. Wang F, et al. Mechanism of thioamide drug action against tuberculosis and leprosy.J Exp Med. 2007 Jan 22;204(1):73-8. [2]. Fajardo TT, et al. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am J Trop Med Hyg. 2006 Mar;74(3):457-61. |
